Joint Formulary & PAD

Sufentanil - Pain

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Sublingual tablets
Associated Icons :
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Sufentanil
Indication :
Pain
Group Name :
Keywords :
Brand Names Include :
Dzuveo
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Sufentanil is used to treat.

  • No records returned.

Committee Recommendations (1)

22 Nov 23 - Not Set

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.